2024
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.Peer-Reviewed Original ResearchHigh-grade serous ovarian cancerClear cell carcinomaHER2-targeting antibody-drug conjugateAntibody-drug conjugatesT-DXdReceptor over-expressionTrastuzumab deruxtecanXenograft modelCell linesOvarian clear cell carcinomaOvarian cancer cell linesTumors overexpressing HER2Biologically aggressive tumorsFluorescence in situ hybridization assaySerous ovarian cancerEffective antibody-drug conjugatesIn vivo antitumor activityMouse xenograft modelMetastatic cell linesDS-8201aCancer cell linesAggressive tumorsHER2 expressionCell carcinomaOvarian cancer
2022
The modeled CA-125 elimination rate constant k (KELIM) score as a predictor of treatment response in patients with advanced high grade serous ovarian cancer (190)
Piedimonte S, Kim S, Clark M, Lheureux S, May T, Bernardini M, Atenafu E. The modeled CA-125 elimination rate constant k (KELIM) score as a predictor of treatment response in patients with advanced high grade serous ovarian cancer (190). Gynecologic Oncology 2022, 166: s109. DOI: 10.1016/s0090-8258(22)01417-2.Peer-Reviewed Original ResearchHigh-grade serous ovarian cancerAdvanced high-grade serous ovarian cancerPlatinum-free intervalSerous ovarian cancerNeoadjuvant chemotherapyOverall survivalCA 125BRCA statusOvarian cancerHigh CA 125 levelsMedian platinum-free intervalKaplan-Meier survival analysisGrade serous ovarian cancerBaseline CA-125Lower median PFSCA-125 levelsPlatinum-resistant diseasePlatinum-sensitive diseaseRetrospective cohort studyTertiary cancer centerDays of chemotherapySubset of patientsCA 125 valuesBRCA mutation statusSignificant differences